Biotech News

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals (VRCA)Verrica Pharmaceuticals2026-06-25 13:46 ESTEarnings

VRCA (VRCA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vrca.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica to Participate in the Jefferies Global Healthcare Conference

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

VRCAVerrica Pharmaceuticals2026-06-25 13:46 EST

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

View all latest news

Verrica Pharmaceuticals

Verrica Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

VRCAVerrica Pharmaceuticals2026-06-26 08:45 EST

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

VRCAVerrica Pharmaceuticals2026-06-26 08:45 EST

Verrica to Participate in the Jefferies Global Healthcare Conference

VRCAVerrica Pharmaceuticals2026-06-26 08:45 EST

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

VRCAVerrica Pharmaceuticals2026-06-26 08:45 EST

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

VRCAVerrica Pharmaceuticals2026-06-26 08:45 EST

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States